Back to Journals » Drug Design, Development and Therapy » Volume 13

Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy

Authors Bova M, Valerieva A, Wu MA, Senter R, Perego F

Received 4 July 2019

Accepted for publication 20 September 2019

Published 22 October 2019 Volume 2019:13 Pages 3635—3646

DOI https://doi.org/10.2147/DDDT.S192475

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 2

Editor who approved publication: Professor Manfred Ogris


Maria Bova,1 Anna Valerieva,2 Maddalena Alessandra Wu,3 Riccardo Senter,4 Francesca Perego5

1Department of Translational Medical Sciences and Interdepartmental Center for Research in Basic and Clinical Immunology Sciences, University of Naples Federico II, Naples, Italy; 2Clinical Centre of Allergology, Medical University of Sofia, Sofia, Bulgaria; 3Department of Biomedical Science, University of Milan, Milan, Italy; 4Department of Medicine, University of Padova, Padova, Italy; 5Department of Cure Subacute, Istituti Clinici Scientifici Maugeri, IRCCS, Milan, Italy

Correspondence: Francesca Perego
Department of Cure Subacute, Istituti Clinici Scientifici Maugeri, IRCCS, via Camaldoli 64, Milan 20138, Italy
Tel +39 3489050440
Email francesca.perego@icsmaugeri.it

Abstract: Despite the efficacy of the on-demand treatment for the control of acute attacks of Hereditary Angioedema due to C1-Inhibitor Deficiency (C1-INH-HAE), the number and severity of attacks and the impairment in the quality of life of the affected patients have led to the development of a new monoclonal antibody, lanadelumab, directly addressed to the blockage of bradykinin, the principal mediator of vasodilation during angioedema attacks. It is indicated for the prophylactic treatment, it is easy to administer, highly effective and with known limited side effects. The current review summarizes the development of the drug, its clinical background and its perspectives.

Keywords: C1-inhibitor hereditary angioedema, long-term prophylaxis, lanadelumab, monoclonal antibody, rare disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]